Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Change in Account Payables (2016 - 2025)

Wave Life Sciences' Change in Account Payables history spans 11 years, with the latest figure at $1.2 million for Q4 2025.

  • For Q4 2025, Change in Account Payables fell 66.59% year-over-year to $1.2 million; the TTM value through Dec 2025 reached -$561000.0, down 116.4%, while the annual FY2025 figure was -$561000.0, 116.4% down from the prior year.
  • Change in Account Payables reached $1.2 million in Q4 2025 per WVE's latest filing, up from $59000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $6.1 million in Q2 2024 to a low of -$5.1 million in Q3 2024.
  • Average Change in Account Payables over 5 years is $94000.0, with a median of $205000.0 recorded in 2023.
  • The largest YoY upside for Change in Account Payables was 2701.38% in 2024 against a maximum downside of 1109.54% in 2024.
  • A 5-year view of Change in Account Payables shows it stood at -$232000.0 in 2021, then surged by 535.78% to $1.0 million in 2022, then plummeted by 81.01% to $192000.0 in 2023, then soared by 1702.08% to $3.5 million in 2024, then plummeted by 66.59% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for WVE's Change in Account Payables are $1.2 million (Q4 2025), $59000.0 (Q3 2025), and $276000.0 (Q2 2025).